Invention Grant
- Patent Title: Anti-epidermal growth factor receptor (EGFR) antibodies
-
Application No.: US16784166Application Date: 2020-02-06
-
Publication No.: US11261255B2Publication Date: 2022-03-01
- Inventor: Weidong Jiang , Pei-Hua Lin
- Applicant: Shanghai Henlius Biotech, Inc.
- Applicant Address: CN Shanghai
- Assignee: Shanghai Henlius Biotech, Inc.
- Current Assignee: Shanghai Henlius Biotech, Inc.
- Current Assignee Address: CN Shanghai
- Agency: Morrison & Foerster LLP
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K47/68 ; A61K39/395 ; G01N33/574 ; A61K39/00

Abstract:
Provided are anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-EGFR antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects.
Public/Granted literature
- US20200223929A1 ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ANTIBODIES Public/Granted day:2020-07-16
Information query